Ikervis (Ciclosporin)

Ciclosporin binds to the intracellular protein cyclophilin, forming a complex that inhibits the enzyme calcineurin. This inhibition blocks activation of T‑cells and the release of inflammatory cytokines, thereby decreasing inflammation on the ocular surface and supporting tear film function.

The dosing regimen for Ikervis is determined by the prescribing clinician. Typically, one drop is instilled in each affected eye once daily, but the exact frequency and duration are individualized based on the patient’s response and severity of disease.

Safety data for ciclosporin ophthalmic use in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so clinicians must weigh potential benefits against possible risks before prescribing to pregnant or nursing women.

To order Ikervis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Ikervis is another topical ciclosporin formulation (e.g., Restasis) or the integrin antagonist lifitegrast (Xiidra). Ikervis uses a 0.1% concentration and an oil‑in‑water emulsion that may improve tolerability for some patients, while lifitegrast works via a different mechanism targeting lymphocyte function‑associated antigen‑1.

Ikervis should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing. Do not use the product if the emulsion appears discoloured or if the seal is broken.

Instill one drop of Ikervis into each affected eye as directed by the prescriber, usually once daily. Wash hands before use, avoid touching the tip of the bottle to the eye or any surface, and close the cap securely after each application.

Serious risks include ocular infection, significant increase in intra‑ocular pressure, corneal ulceration, severe allergic reactions, and rare cases of vision loss. Patients should report any sudden pain, redness, discharge, or visual changes to their eye care professional promptly.

Ikervis is contraindicated in individuals with known hypersensitivity to ciclosporin or any formulation excipients, and in patients with active ocular infections. Caution is also advised for those with uncontrolled glaucoma or severe ocular surface disease until evaluated by a specialist.